

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/010987 A3

- (51) International Patent Classification⁷: **A61K 31/13**, 31/137, 45/00, A61P 9/04, 9/06, 9/10
- (21) International Application Number: **PCT/EP2003/008085**
- (22) International Filing Date: 23 July 2003 (23.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0217152.8 24 July 2002 (24.07.2002) GB
- (71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BRINKMANN, Volker** [DE/DE]; Sternwaldstrasse 31, 79102 Freiburg (DE). **FEUTREN, Gilles** [FR/FR]; 31, rue du Belvédère, F-68100 Mulhouse (FR). **HOF, Robert, Paul** [CH/CH]; Huebacherweg 12, CH-4460 Gelterkinden (CH).
- (74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
15 April 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF S1P RECEPTOR AGONISTS IN HEART DISEASES

(57) Abstract: The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.

WO 2004/010987 A3

Publication No. **521 29**

IPC 7 A61K31/13 A61K31/137 A61K45/00
A61P9/10

A61P9/04

A61P9/06

9/06 JAN 2005

B. FIELDS SEARCHED

IPC 7 A61K

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Relevant to claim No.

X	KARLINER J S: "Lysophospholipids and the cardiovascular system" BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER,, vol. 1582, no. 1-3, 23 May 2002 (2002-05-23), pages 216-221, XP004366543 page 219, left-hand column, paragraph 2 - right-hand column, paragraph 4
---	--

1-4

X PYNE S ET AL: "SPINGOSINE 1-PHOSPHATE
SIGNALLING VIA THE ENDOTHELIAL
DIFFERENTIATION GENE FAMILY OF
G-PROTEIN-COUPLED RECEPTORS"
PHARMACOLOGY AND THERAPEUTICS, ELSEVIER,
GB,
vol. 88, 2000, pages 115-131, XP002254562
ISSN: 0163-7258
page 127, left-hand column, paragraph 1-3

1-4

— / —

X Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

& document member of the same patent family

28 October 2003

19.02.2004

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Young, A

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/EP 03/08085

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 004 565 A (CHIBA KENJI ET AL) 21 December 1999 (1999-12-21) column 3, line 20 - column 5, line 7 column 8, line 15 -----	1-4,7
X	LILIOM KAROLY ET AL: "Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: A possible role in regulating cardiac function via sphingolipid receptors" BIOCHEMICAL JOURNAL, vol. 355, no. 1, 1 April 2001 (2001-04-01), pages 189-197, XP002258995 ISSN: 0264-6021 page 196, left-hand column, paragraph 4 - right-hand column, paragraph 1 -----	1-4
X	EP 0 627 406 A (YOSHITOMI PHARMACEUTICAL) 7 December 1994 (1994-12-07) cited in the application the whole document -----	1-4,7
A	CLELAND J G F ET AL: "WHAT IS THE OPTIMAL MEDICAL MANAGEMENT OF ISCHAEMIC HEART FAILURE?" BRITISH MEDICAL BULLETIN, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 59, 2001, pages 135-148, XP008017622 ISSN: 0007-1420 the whole document -----	5,6
A	LYNCH K R: "Lysophospholipid receptor nomenclature" BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, vol. 1582, no. 1-3, 23 May 2002 (2002-05-23), pages 70-71, XP004366523 the whole document -----	1-7
X,P	WO 03/020313 A (ONO PHARMACEUTICAL CO ;NAKADE SHINJI (JP); SUZUKI HIDEHIRO (JP)) 13 March 2003 (2003-03-13) abstract -----	1-7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/08085

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 4,6 and 7 (part) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-7 (part)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: -

Present claims 1-6 relate to a product/compound/method defined by reference to a desirable characteristic or property, namely S1P receptor agonist.

The claims cover all products/compounds/methods having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/compounds/methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/compound/method/apparatus by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products/compounds/methods as disclosed in claim 7 (i.e. formula I for invention 1).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-7 (part)

Use, a pharmaceutical composition, a pharmaceutical combination or a method according to claims 1-6 wherein the S1P receptor agonist is selected from a compound of formula I.

2. claims: Claims 1-7 (part)

Use, a pharmaceutical composition, a pharmaceutical combination or a method according to claim 1-6 wherein the S1P receptor agonist is selected from a compound of formula II.

3. claims: Claims 1-7 (part)

Use, a pharmaceutical composition, a pharmaceutical combination or a method according to claims 1-6 wherein the S1P receptor agonist is selected from a compound of formula III.

4. claims: Claims 1-7 (part)

Use, a pharmaceutical composition, a pharmaceutical combination or a method according to claims 1-6 wherein the S1P receptor agonist is selected from a compound of formula IVa or IVb.

5. claims: Claims 1-7 (part)

Use, a pharmaceutical composition, a pharmaceutical combination or a method according to claims 1-6 wherein the S1P receptor agonist is selected from a compound of formula V.

6. claims: Claims 1-7 (part)

Use, a pharmaceutical composition, a pharmaceutical combination or a method according to claims 1-6 wherein the S1P receptor agonist is selected from a compound of formula VI.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/08085

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6004565	A	21-12-1999	JP 11080026 A	23-03-1999
			US 2002102279 A1	01-08-2002
EP 0627406	A	07-12-1994	CA 2126337 A1	28-04-1994
			DE 69321823 D1	03-12-1998
			DE 69321823 T2	02-06-1999
			DK 627406 T3	12-07-1999
			EP 0627406 A1	07-12-1994
			HK 1013281 A1	02-06-2000
			US 5604229 A	18-02-1997
			AT 172711 T	15-11-1998
			CY 2215 A	18-04-2003
			ES 2126658 T3	01-04-1999
			WO 9408943 A1	28-04-1994
			JP 2579602 B2	05-02-1997
			KR 155015 B1	01-12-1998
			US 5719176 A	17-02-1998
			US 5952316 A	14-09-1999
WO 03020313	A	13-03-2003	WO 03020313 A1	13-03-2003

U.S. NAT

AL STAGE WORKSHEET

(EO)

U.S. APPL. NO.

10/521297

INTERNATIONAL APPL.

EP2003/08085

APPLICATION FILED BY: 20 MOS., _____ OR 30 MOS., _____

SCREENED BY

INTERNATIONAL APPLICATION PAPERS IN THE APPLICATION FILE:

- ☒ International application
☒ Article 19 amendments
☒ Priority Document(s) No. _____
☒ Request Form PCT/RO/101
☐ PCT/IB/302
☐ PCT/IB/304
☐ PCT/IB/306
☐ PCT/IB/308
☐ PCT/IB/331
☒ OTHER PCT/IB/ _____
☒ PCT/PBA/409 also 416

- ☒ 409 annexes to IPR
☒ PCT/ISA/210 (Search report)
☐ Search report References
☐ Other Papers filed

WIPO PUBLICATION
PUBLICATION NO. WC 2004/101098
PUBLICATION DATE 05 Feb 84
PUBLICATION LANG. English
NOT PUBLISHED
____ U.S. only _____ Requested

RECEIVED FROM THE APPLICANT: (other than checked above)

- ☒ National application basic fee paid
☒ Express Processing Requested
☒ Translation of the International Application
☒ Used the IB copy of the IA
☒ Description
☒ Claims
☒ Drawings
☒ Foreign Language in drawing
☒ Article 19 Amendments
☒ Amendment used in application
☒ Article 34 Amendment
☒ Amendment used in application
☒ DNA
☒ 1194 transaction done

- ☒ Preliminary Amendment(s) filed 14 Jan 05
____ second submission
☒ Information Disclosure Statement 17 Mar 05
____ second submission
☐ Assignment
____ Forward to Assignment Branch
☐ Substitute Specification
☒ Small Entity Statement
____ type
☐ Oath/Declaration (date submitted _____)
☒ Not executed
☒ Executed
☐ Power of Attorney
☐ Change of Address

USC Receipt of Request (PTO -- 1399 Transmittal Letter)
te Acceptable oath/declaration received

2(e) Datete complete 35 USC 371 requirements met

DATE NOTICE COMPLETED

1/EO 903 Notice of Acceptance1/EO 905 Notice of Missing Requirements1/EO 917 Notice of A defective oath or declaration1/EO 916 Notice of defective response

BEST AVAILABLE COPY